早期檢測 守護健康
患者故事
Personalizing Metastatic Breast Cancer Treatment Through Liquid Biopsy | Dr. Shane Dormady
Dr. Shane Dormady, MD, PhD, Ocampo Family Medical Director of Oncology at El Camino Health, shares how liquid biopsy can uncover actionable mutations to support personalized treatment strategies for metastatic breast cancer, helping improve patient outcomes through targeted therapy.
LiquidHALLMARK® by Lucence is an ultra-sensitive liquid biopsy test that analyzes ctDNA and ctRNA to enable tailored treatment decisions. Speak to your healthcare provider to seek advice on your options.
患者故事
The Emerging Role of Clonal Hematopoiesis in Personalized Risk Evaluation | Dr. Raj Patel
Dr. Raj Patel, a Board-certified physician with over three decades of clinical experience, discusses the emerging role of clonal hematopoiesis (CH) testing and how blood-based genetic insights may help evaluate hidden cardiovascular and leukemia risks, supporting earlier intervention and more personalized preventive care.
CardioHemeRISK™ is a liquid biopsy-based NGS test that detects aging and lifestyle-related CH mutations using Lucence’s mirror barcoding technology. Speak to your healthcare provider to seek advice on your options.
最新消息
